company background image
INCR

InterCure TASE:INCR Stock Report

Last Price

₪20.27

Market Cap

₪914.9m

7D

3.5%

1Y

-12.4%

Updated

24 Jun, 2022

Data

Company Financials +
INCR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health4/6
Dividends0/6

INCR Stock Overview

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally.

InterCure Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for InterCure
Historical stock prices
Current Share Price₪20.27
52 Week High₪26.35
52 Week Low₪17.85
Beta-0.47
1 Month Change-10.55%
3 Month Change-8.24%
1 Year Change-12.37%
3 Year Change-37.37%
5 Year Change869.32%
Change since IPO-100.00%

Recent News & Updates

Shareholder Returns

INCRIL PharmaceuticalsIL Market
7D3.5%2.7%4.0%
1Y-12.4%-36.4%7.1%

Return vs Industry: INCR exceeded the IL Pharmaceuticals industry which returned -36.4% over the past year.

Return vs Market: INCR underperformed the IL Market which returned 7.1% over the past year.

Price Volatility

Is INCR's price volatile compared to industry and market?
INCR volatility
INCR Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement7.8%
Market Average Movement5.6%
10% most volatile stocks in IL Market8.8%
10% least volatile stocks in IL Market3.7%

Stable Share Price: INCR is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: INCR's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994350Alex Rabinovichhttps://www.intercure.co

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector.

InterCure Fundamentals Summary

How do InterCure's earnings and revenue compare to its market cap?
INCR fundamental statistics
Market Cap₪914.87m
Earnings (TTM)₪14.85m
Revenue (TTM)₪273.86m

61.6x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INCR income statement (TTM)
Revenue₪273.86m
Cost of Revenue₪146.70m
Gross Profit₪127.16m
Other Expenses₪112.30m
Earnings₪14.85m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.33
Gross Margin46.43%
Net Profit Margin5.42%
Debt/Equity Ratio21.9%

How did INCR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is INCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INCR?

Other financial metrics that can be useful for relative valuation.

INCR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA16.7x
PEG Ratio0.7x

Price to Earnings Ratio vs Peers

How does INCR's PE Ratio compare to its peers?

INCR PE Ratio vs Peers
The above table shows the PE ratio for INCR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average19x

Price-To-Earnings vs Peers: INCR is expensive based on its Price-To-Earnings Ratio (61.6x) compared to the peer average (19x).


Price to Earnings Ratio vs Industry

How does INCR's PE Ratio compare vs other companies in the Pharmaceuticals Industry?

Price-To-Earnings vs Industry: INCR is expensive based on its Price-To-Earnings Ratio (61.6x) compared to the Asian Pharmaceuticals industry average (22x)


Price to Earnings Ratio vs Fair Ratio

What is INCR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INCR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.6x
Fair PE Ratio86.3x

Price-To-Earnings vs Fair Ratio: INCR is good value based on its Price-To-Earnings Ratio (61.6x) compared to the estimated Fair Price-To-Earnings Ratio (86.3x).


Share Price vs Fair Value

What is the Fair Price of INCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: INCR (₪20.27) is trading above our estimate of fair value (₪0.68)

Significantly Below Fair Value: INCR is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: INCR is good value based on its PEG Ratio (0.7x)


Discover undervalued companies

Future Growth

How is InterCure forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


90.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INCR's forecast earnings growth (90.7% per year) is above the savings rate (1.5%).

Earnings vs Market: INCR's earnings (90.7% per year) are forecast to grow faster than the IL market (3.9% per year).

High Growth Earnings: INCR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INCR's revenue (25.9% per year) is forecast to grow faster than the IL market (4% per year).

High Growth Revenue: INCR's revenue (25.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INCR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has InterCure performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: INCR has high quality earnings.

Growing Profit Margin: INCR's current net profit margins (5.4%) are lower than last year (14.1%).


Past Earnings Growth Analysis

Earnings Trend: INCR has become profitable over the past 5 years, growing earnings by -2.9% per year.

Accelerating Growth: INCR's earnings growth over the past year (12.6%) exceeds its 5-year average (-2.9% per year).

Earnings vs Industry: INCR earnings growth over the past year (12.6%) exceeded the Pharmaceuticals industry 9%.


Return on Equity

High ROE: INCR's Return on Equity (3.7%) is considered low.


Discover strong past performing companies

Financial Health

How is InterCure's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: INCR's short term assets (₪374.2M) exceed its short term liabilities (₪223.5M).

Long Term Liabilities: INCR's short term assets (₪374.2M) exceed its long term liabilities (₪35.7M).


Debt to Equity History and Analysis

Debt Level: INCR has more cash than its total debt.

Reducing Debt: INCR's debt to equity ratio has increased from 16.3% to 21.9% over the past 5 years.

Debt Coverage: INCR's debt is not well covered by operating cash flow (18.3%).

Interest Coverage: INCR's interest payments on its debt are well covered by EBIT (57.6x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is InterCure current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate INCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INCR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INCR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as INCR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Alex Rabinovich (50 yo)

3.42yrs

Tenure

₪180,000

Compensation

Mr. Alexander Rabinovich, also known as Alex, is Chief Executive Officer and Director of InterCure Ltd. since January 1, 2019 and July 9, 2018 respectively. Mr. Rabinovich is Chief Executive Officer and Di...


CEO Compensation Analysis

Compensation vs Market: Alex's total compensation ($USD52.13K) is below average for companies of similar size in the IL market ($USD551.97K).

Compensation vs Earnings: Alex's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: INCR's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: INCR's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.


Top Shareholders

Company Information

InterCure Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: InterCure Ltd.
  • Ticker: INCR
  • Exchange: TASE
  • Founded: 1994
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₪914.865m
  • Shares outstanding: 45.13m
  • Website: https://www.intercure.co

Number of Employees


Location

  • InterCure Ltd.
  • 85 Medinat ha-Yehudim Street
  • Herzliya
  • 4676670
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/23 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.